Thomas Visalli

Affiliations
  • Eisai Inc., Global Nonclinical Regulatory, Nutley, NJ, 07110, USA.

Publications (1)

An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.

Cancer chemotherapy and pharmacology
Avec: Bart A Jessen , Paul Cornwell , Sean Redmond , Thomas Visalli , Marie Lemper , Todd Bunch , Timothy Hart

Réseau de co-auteurs

Bart A Jessen 1 collaboration
Paul Cornwell 1 collaboration
Sean Redmond 1 collaboration
Marie Lemper 1 collaboration
Todd Bunch 1 collaboration
Timothy Hart 1 collaboration